Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP lessened its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 79.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,934 shares of the company’s stock after selling 87,851 shares during the period. GSA Capital Partners LLP’s holdings in Health Catalyst were worth $187,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of HCAT. Nisa Investment Advisors LLC raised its holdings in shares of Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares in the last quarter. Quarry LP grew its holdings in shares of Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Health Catalyst during the 3rd quarter valued at about $59,000. Perfromance Wealth Partners LLC bought a new position in shares of Health Catalyst during the 2nd quarter worth approximately $64,000. Finally, Mackenzie Financial Corp bought a new position in Health Catalyst during the 2nd quarter valued at about $70,000. 85.00% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30. Following the sale, the chief operating officer now owns 129,690 shares of the company’s stock, valued at $998,613. The trade was a 3.86 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,068 shares of company stock valued at $257,555. 2.50% of the stock is owned by company insiders.

Health Catalyst Stock Performance

Shares of Health Catalyst stock opened at $8.13 on Monday. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41. The business has a fifty day simple moving average of $8.13 and a two-hundred day simple moving average of $7.27. The firm has a market capitalization of $494.71 million, a P/E ratio of -6.02 and a beta of 1.32. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) EPS. On average, equities analysts forecast that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on HCAT. Stephens boosted their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Citigroup boosted their price target on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. boosted their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Evercore ISI raised their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Finally, Piper Sandler cut their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and an average target price of $11.71.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.